• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Chemours (CC) Faces Expanded PFAS RICO Suit In Firefighter Gear Case Is Its Risk Story Shifting?

    Simply Wall St·01/07/2026 08:38:03
    Listen to the news
    • On January 6, 2026, a Montana federal judge refused to dismiss a class-action lawsuit accusing DuPont/Chemours, 3M and others of concealing PFAS risks in firefighter turnout gear, allowing RICO and multi-state claims to proceed.
    • The ruling keeps Chemours exposed to allegations of a coordinated effort to hide PFAS dangers, with potential equipment replacement costs for over one million firefighters estimated in the billions.
    • We’ll now examine how this expanded PFAS litigation exposure, including potential RICO liability, may influence Chemours’ existing investment narrative and risk profile.

    Uncover the next big thing with financially sound penny stocks that balance risk and reward.

    Chemours Investment Narrative Recap

    To own Chemours, you need to believe its fluoroproducts, advanced materials and TiO₂ portfolio can offset ongoing PFAS overhangs and recent earnings volatility. The Montana ruling keeps PFAS and potential RICO liability squarely in focus, reinforcing that unresolved legal exposure remains one of the biggest near term risks, while not clearly changing the core product demand catalysts that underpin most investment cases today.

    Against this backdrop, Chemours’ 2025 guidance, reaffirming full year net income expectations despite earlier quarterly losses, is an important reference point for how management is framing near term performance. That outlook now sits alongside expanding PFAS litigation risk, and investors watching for improving cash generation, Opteon growth and TiO₂ leverage will likely weigh any future legal developments against the company’s ability to execute on those operational goals.

    Yet behind the headline opportunity, investors should also be aware of the unresolved PFAS litigation risk and its potential cash flow impact...

    Read the full narrative on Chemours (it's free!)

    Chemours’ narrative projects $6.6 billion revenue and $671.0 million earnings by 2028. This requires 3.9% yearly revenue growth and about a $1.1 billion earnings increase from -$412.0 million today.

    Uncover how Chemours' forecasts yield a $17.78 fair value, a 34% upside to its current price.

    Exploring Other Perspectives

    CC 1-Year Stock Price Chart
    CC 1-Year Stock Price Chart

    Five members of the Simply Wall St Community value Chemours between US$11.55 and US$42.91 per share, showing how far apart individual views can be. You are weighing those opinions against the reality that expanding PFAS litigation and potential RICO exposure could influence Chemours’ future cash flows and balance sheet strength in ways that many earlier assessments may not yet reflect.

    Explore 5 other fair value estimates on Chemours - why the stock might be worth 13% less than the current price!

    Build Your Own Chemours Narrative

    Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

    Want Some Alternatives?

    Every day counts. These free picks are already gaining attention. See them before the crowd does:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.